scholarly journals First identification of SARS-CoV-2 Lambda (C.37) variant in Southern Brazil

2021 ◽  
Author(s):  
Priscila Lamb Wink ◽  
Fabiana Caroline Zempulski Volpato ◽  
Francielle Liz Monteiro ◽  
Julia Biz Willig ◽  
Alexandre P. Zavascki ◽  
...  
Keyword(s):  
South America ◽  
World Health Organization ◽  
World Health ◽  
Southern Brazil ◽  
First Report ◽  
Spike Gene ◽  
High Prevalence ◽  
The World ◽  
Health Organization

In June 15, 2021, the lineage Lambda (C.37) of SARS-CoV-2 was considered a variant of interest (VOI) by the World Health Organization. This lineage has high prevalence in some South America countries but it was described only occasionally in Brazil. Here we describe the first report of the SARS-CoV-2 Lambda variant in Southern Brazil. The sequence described in this paper presented all the eight C.37 defining lineage mutations (ORF1a gene: del916;3675-3677; Spike gene: del16;246-252, G75V, T76I, L452Q, F490S, D614G, and T859N) in addition to other 19 mutations. Considering that this VOI has been associated with high rates of transmissibility, the possible spread in the Southern Brazilian community is a matter of concern.

scholarly journals The Emergence of SARS-CoV-2 Variant Lambda (C.37) in South America

2021 ◽  
Author(s):  
Pedro E. Romero ◽  
Alejandra Davila-Barclay ◽  
Guillermo Salvatierra ◽  
Luis Gonzalez ◽  
Diego Cuicapuza ◽  
...  
Keyword(s):  
South America ◽  
World Health Organization ◽  
World Health ◽  
Spike Gene ◽  
Synonymous Mutations ◽  
The World ◽  
The Usa ◽  
Alpha Beta ◽  
Health Organization

We report the emergence of a novel lineage of SARS-CoV-2 in South America, termed C.37. It presents a deletion in the ORF1a gene (Δ3675-3677), also found in variants of concern (VOCs) Alpha, Beta, and Gamma, and seven non-synonymous mutations in the Spike gene (Δ247-253, G75V, T76I, L452Q, F490S, T859N). Initially reported in Lima, Peru, in late December 2020, it now accounts for almost 100% of Peruvian genomes in April 2021. It is expanding in Chile and Argentina, and there is evidence of onward transmission in Colombia, Mexico, the USA, Germany, and Israel. On June 15, 2021, the World Health Organization designated C.37 as Variant of Interest (VOI) Lambda.

scholarly journals An Overview on Lambda, Epsilon, Kappa, Iota and Zeta Variants of Covid-19 and its Probability to Merge with Delta & Delta Plus, why it is a Concern

2021 ◽  
Vol 12 (5) ◽  
pp. 6895-6914
Keyword(s):  
World Health Organization ◽  
Neutralizing Antibodies ◽  
Spike Protein ◽  
World Health ◽  
South American ◽  
Infected Person ◽  
High Prevalence ◽  
The World ◽  
Health Organization

COVID-19 is caused by the virus SARS-CoV-2 that belongs to the Corona groups. The subgroups of the coronavirus families are α, β, γ, and δ coronavirus. On June 15, 2021, the string λ of SARS-CoV-2 was evaluated as a variant of interest via the World Health Organization. This string has a high prevalence in some parts of South American countries, but it occurred only occasionally in Brazil. This study confirms that mutations in the λ -spike protein can be destroyed the neutralizing antibodies and increase infectivity. Coronaviruses such as SARS-CoV-2 have an evolutionary superpower called “recombination” which permits the mixing of their genomes into novel combinations. Unlike regular mutation, which precedes slowly one change at a time, recombination can produce whole changes in a coronavirus genome. Although right now, δ-variant is a concern, a mixing of λ with other variants such as δ-variant is much more of a concern compared to alone variants. There is another item: the recombination can arise within the sample after it was taken from the infected person, not while it was inside their body.

scholarly journals AMOR's new Editor-in-Chief: Collaborative endeavor is vital for cancer researchers

2017 ◽  
Vol 3 (1) ◽  
pp. 4
Author(s):  
Editorial Office
Keyword(s):  
South America ◽  
Global Health ◽  
World Health Organization ◽  
World Health ◽  
Newly Diagnosed ◽  
Health Challenge ◽  
The World ◽  
Health Organization ◽  
Global Health Challenge

<p>Cancer is a pressing global health challenge, asserts AMOR’s new Editor-in-Chief (EIC) Dr. Kwong Kwok Wong.“According to the estimation by the World Health Organization, there were 14 million new cases and 8.2 million cancer deaths in 2012,” he tells AMOR Media in an exclusive interview. “By the year 2030, the number of newly-diagnosed cancer cases will increase globally to 22 million and 70% of all cancer deaths will likely occur in low- and medium-income countries in Africa, Asia, and Central and South America,” he adds.</p>

scholarly journals Are We on Our Way to Achieving the 2020 Goals for Schistosomiasis Morbidity Control Using Current World Health Organization Guidelines?

2018 ◽  
Vol 66 (suppl_4) ◽  
pp. S245-S252 ◽  
Author(s):  
Jaspreet Toor ◽  
Ramzi Alsallaq ◽  
James E Truscott ◽  
Hugo C Turner ◽  
Marleen Werkman ◽  
...  
Keyword(s):  
World Health Organization ◽  
Public Health Problem ◽  
Monitoring And Evaluation ◽  
Wash Water ◽  
World Health ◽  
Treatment Coverage ◽  
Hygiene Measures ◽  
High Prevalence ◽  
The World ◽  
Health Organization

Abstract Background Schistosomiasis remains an endemic parasitic disease affecting millions of people around the world. The World Health Organization (WHO) has set goals of controlling morbidity to be reached by 2020, along with elimination as a public health problem in certain regions by 2025. Mathematical models of parasite transmission and treatment impact have been developed to assist in controlling the morbidity caused by schistosomiasis. These models can inform and guide implementation policy for mass drug administration programs, and help design monitoring and evaluation activities. Methods We use these models to predict whether the guidelines set by the WHO are on track for achieving their 2020 goal for the control of morbidity, specifically for Schistosoma mansoni. We examine whether programmatic adaptations; namely increases in treatment coverage and/or expansion to adult inclusion in treatment, will improve the likelihood of reaching the WHO goals. Results We find that in low-prevalence settings, the goals are likely to be attainable under current WHO guidelines, but in moderate to high-prevalence settings, the goals are less likely to be achieved unless treatment coverage is increased and expanded to at least 85% for school-aged children and 40% for adults. Conclusions To improve the likelihood of reaching the WHO goals, programmatic adaptations are required, particularly for moderate- to high-prevalence settings. Furthermore, improvements in adherence to treatment, potential development of candidate vaccines, and enhanced snail control and WASH (water, sanitation, and hygiene) measures will all assist in achieving the goals.

Erstes Instrument zur standardisierten Erfassung der Teilhabe Behinderter

2017 ◽  
Vol 79 (07) ◽  
pp. 526-527
Keyword(s):  
World Health Organization ◽  
World Health ◽  
The World ◽  
Health Organization ◽  
Menschen Mit Behinderung

Coenen M et al. [Recommendation for the collection and analysis of data on participation and disability from the perspective of the World Health Organization]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2016; 59: 1060–1067 Um eine gleichberechtigte Teilhabe an der Gesellschaft von Menschen mit Behinderung zu ermöglichen, werden zunächst Daten zu vorhandenen Einschränkungen gebraucht. Erst wenn diese detailliert erhoben wurden, können Konzepte zur Beseitigung von Problemen entwickelt werden. Ein standardisiertes Erhebungsinstrument für alle Aspekte der Funktionsfähigkeit fehlte jedoch bisher.

Sign in / Sign up

Export Citation Format

Share Document